Results of the mean RCS, mean RP frequency, and mean RP duration in a crossover trial of tadalafil in RP secondary to SSc.
| Baseline | Tadalafil (change from baseline) | Placebo (change from baseline) | p | |
|---|---|---|---|---|
| RCS, cm | 3.76 ± 1.83 | 2.43 ± 2.01 (− 1.33) | 2.53 ± 2.22 (−1.23) | NS |
| RP frequency, per day | 2.93 ± 1.67 | 2.08 ± 1.72 (−0.85) | 2.1 ± 1.78 (−0.83) | NS |
| RP duration, min | 53.42 ± 56.38 | 40.61 ± 63.81 (−12.81) | 47.0 ± 77.60 (−6.42) | NS |
RCS: Raynaud Condition Score; RP: Raynaud Phenomenon; NS: not significant.